vTv Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $36.8M+3,522.3% YoYTTM through 30 Jun 2026
Net Income -$4.8MTTM through 30 Jun 2026
Free Cash Flow -$16.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -25.0% |
| Operating Margin | 63.1% |
| Net Margin | -12.9% |
Returns
2.5%ROE
2.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio14.36x
Net Debt-$98.1Mnet cash position
Cash & Equivalents$86.6M
Quality Metrics
Altman Z-Score4.36
Piotroski F-Score3 / 9
FCF Margin-45.5%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $0
Dividend
No dividend
Capital Allocation
R&D Spend$28.7M
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration and License | $36.8M | View detailsFuture segment revenue is highly dependent on clinical development milestones and potential new partnership agreements. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.